9-ING-41 in Pediatric Patients With Refractory Malignancies.
Public ClinicalTrials.gov record NCT04239092. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or With Irinotecan, Irinotecan Plus Temozolomide, or With Cyclophosphamide Plus Topotecan in Pediatric Patients With Refractory Malignancies.
Study identification
- NCT ID
- NCT04239092
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Actuate Therapeutics Inc.
- Industry
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Interventions
- 9-ING-41 Drug
- Cyclophosphamide Drug
- Irinotecan Drug
- Temozolomide Drug
- Topotecan Drug
Drug
Eligibility (public fields only)
- Age range
- Up to 22 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 4, 2020
- Primary completion
- Jul 6, 2025
- Completion
- Jul 6, 2025
- Last update posted
- Jul 16, 2025
2020 – 2025
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94158-2549 | — |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Mott Children's Hospital | Ann Arbor | Michigan | 48109 | — |
| Levine Cancer Center | Charlotte | North Carolina | 28204 | — |
| Duke Children's Hospital and Health Center, Duke University Medical Center | Durham | North Carolina | 27708 | — |
| Brown University | Providence | Rhode Island | 02912 | — |
| Texas Children's Hospital | Houston | Texas | 77030 | — |
| Seattle Children's Research Institute | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04239092, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04239092 live on ClinicalTrials.gov.